PLSE

Company Overview — What Does PULSE BIOSCIENCES, INC. Do?

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California. PULSE BIOSCIENCES, INC. (PLSE) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Kevin Danahy and employs approximately 140 people, headquartered in HAYWARD, California. With a market capitalization of $1.6B, PLSE is one of the notable companies in the Healthcare sector.

PULSE BIOSCIENCES, INC. (PLSE) Stock Rating — Hold (April 2026)

As of April 2026, PULSE BIOSCIENCES, INC. receives a Hold rating with a composite score of 33.3/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.PLSE ranks #1,833 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PULSE BIOSCIENCES, INC. ranks #185 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PLSE Stock Price and 52-Week Range

PULSE BIOSCIENCES, INC. (PLSE) currently trades at $18.67. The stock lost $0.58 (3.0%) in the most recent trading session. The 52-week high for PLSE is $26.30, which means the stock is currently trading -29.0% from its annual peak. The 52-week low is $12.56, putting the stock 48.6% above its annual trough. Recent trading volume was 260K shares, suggesting relatively thin trading activity.

Is PLSE Overvalued or Undervalued? — Valuation Analysis

PULSE BIOSCIENCES, INC. (PLSE) carries a value factor score of 28/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 16.83x, versus the sector average of 2.75x. The price-to-sales ratio is 15779.79x, compared to 1.66x for the average Healthcare stock.

At current multiples, PULSE BIOSCIENCES, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

PULSE BIOSCIENCES, INC. Profitability — ROE, Margins, and Quality Score

PULSE BIOSCIENCES, INC. (PLSE) earns a quality factor score of 12/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -84.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -72.0% versus the sector average of -33.1%.

On a margin basis, PULSE BIOSCIENCES, INC. reports gross margins of -224.4%, compared to 71.5% for the sector. The operating margin is -23682.6% (sector: -66.1%). Net profit margin stands at -22540.7%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PLSE Debt, Balance Sheet, and Financial Health

PULSE BIOSCIENCES, INC. has a debt-to-equity ratio of 17.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 10.53x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $95M.

PLSE has a beta of 1.23, meaning it is more volatile than the broader market — a $10,000 investment in PLSE would be expected to move 22.7% more than the S&P 500 on any given day. The stability factor score for PULSE BIOSCIENCES, INC. is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

PULSE BIOSCIENCES, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, PULSE BIOSCIENCES, INC. reported revenue of $86,000 and earnings per share (EPS) of $-1.08. Net income for the quarter was $-68M. Gross margin was -224.4%. Operating income came in at $-72M.

In FY 2025, PULSE BIOSCIENCES, INC. reported revenue of $350,000 and earnings per share (EPS) of $-1.08. Net income for the quarter was $-73M. Gross margin was -54.0%. Operating income came in at $-77M.

In Q3 2025, PULSE BIOSCIENCES, INC. reported revenue of $86,000 and earnings per share (EPS) of $-0.29. Net income for the quarter was $-19M. Gross margin was -224.4%. Operating income came in at $-20M.

In Q2 2025, PULSE BIOSCIENCES, INC. reported revenue of $0 and earnings per share (EPS) of $-0.28. Net income for the quarter was $-19M. Operating income came in at $-20M.

Over the past 8 quarters, PULSE BIOSCIENCES, INC. has demonstrated a growth trajectory, with revenue expanding from $0 to $86,000. Investors analyzing PLSE stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PLSE Dividend Yield and Income Analysis

PULSE BIOSCIENCES, INC. (PLSE) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PLSE Momentum and Technical Analysis Profile

PULSE BIOSCIENCES, INC. (PLSE) has a momentum factor score of 58/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 53/100 reflects moderate short selling activity.

PLSE vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, PULSE BIOSCIENCES, INC. (PLSE) ranks #185 out of 838 stocks based on the Blank Capital composite score. This places PLSE in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PLSE against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PLSE vs S&P 500 (SPY) comparison to assess how PULSE BIOSCIENCES, INC. stacks up against the broader market across all factor dimensions.

PLSE Next Earnings Date

No upcoming earnings date has been announced for PULSE BIOSCIENCES, INC. (PLSE) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PLSE? — Investment Thesis Summary

PULSE BIOSCIENCES, INC. presents a balanced picture with arguments on both sides. The quality score of 12/100 flags below-average profitability. The value score of 28/100 indicates premium valuation. High volatility (stability score 35/100) increases portfolio risk.

In summary, PULSE BIOSCIENCES, INC. (PLSE) earns a Hold rating with a composite score of 33.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PLSE stock.

Related Resources for PLSE Investors

Explore more research and tools: PLSE vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PLSE head-to-head with peers: PLSE vs AZN, PLSE vs SLGL, PLSE vs VMD.